Methods for treating at least one condition having MT1 receptor, 5HT2GB receptor, and L-type calcium channel activity

Details for Australian Patent Application No. 2007293107 (hide)

Owner AGI Therapeutics Research Limited

Inventors Martin, Mary; Kelly, John; Devane, John

Agent Watermark

Pub. Number AU-A-2007293107

PCT Pub. Number WO2008/029300

Priority 60/835,447 04.08.06 US; 60/907,052 19.03.07 US

Filing date 18 July 2007

Wipo publication date 13 March 2008

International Classifications

A61P 25/06 (2006.01) Drugs for disorders of the nervous system

A61K 31/277 (2006.01)

Event Publications

26 February 2009 PCT application entered the National Phase

  PCT publication WO2008/029300 Priority application(s): WO2008/029300

10 March 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007293108-Methods for producing fuels and solvents

2007293106-A process for producing thermally stable aluminum trihydroxide particles by wet-milling with subsequent spray drying